Igor Puzanov, MD, medical oncologist, Vanderbilt-Ingram Cancer Center, discusses the potential to partner T-VEC with a targeted agent for the treatment of patients with melanoma.
Igor Puzanov, MD, medical oncologist, Vanderbilt-Ingram Cancer Center, discusses the potential to partner T-VEC with a targeted agent for the treatment of patients with melanoma.
Learn about targeted agents for the treatment of melanoma > >
Management of Immune-Related Toxicities in Melanoma Has Improved Over Time
April 24th 2024During a Case-Based Roundtable® event, Evan J. Lipson, MD, discussed with participants how their experience with immunotherapy toxicities has changed over time in the first article of a 2-part series.
Read More
Novel Approaches Focus on Limiting Toxicity in Older Patients With ALL
April 22nd 2024The major challenges for clinicians treating older patients with acute lymphoblastic leukemia surround the emergence of resistance to existing therapies and the toxicities associated with current chemotherapies.
Read More